Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964323 · ClinicalTrials.gov registry record
Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
A clinical trial, sponsored by Agios Pharmaceuticals.
- Terminated
- Registry status
- 15
- Enrollment target
NCT04964323 is a clinical trial that was terminated before completion, run by Agios Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04964323 was terminated before completion, sponsored by Agios Pharmaceuticals.
- TERMINATED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The primary objective of this study is to understand and characterize the health-related quality of life (HRQoL) and disease burden of adult participants with PK deficiency receiving routine clinical care. This study is an observational (i.e., noninterventional), longitudinal, multicenter, global registry for participants with PK deficiency, a rare nonspherocytic hemolytic anemia. This study will be open for enrollment for 2 years and all enrolled participants will be followed prospectively for up to 96 weeks. Data will be collected from participants who have provided informed consent and authorization pursuant to applicable laws and regulations.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964323
The ClinicalTrials.gov registry entry for NCT04964323 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04964323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964323 about?
NCT04964323 is a clinical study titled "Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)". The primary objective of this study is to understand and characterize the health-related quality of life (HRQoL) and disease burden of adult participants with PK deficiency receiving routine clinical care. This study is an observational (i.e., noninterventional), longitudinal, multicenter, global re...
What is the current status of trial NCT04964323?
This trial is currently terminated. The enrollment target is 15 participants. The study started on 2021-07-02. Estimated completion is 2023-06-30.
Who is sponsoring clinical trial NCT04964323?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.